Table 1.

Study results

Migraine frequency
Average number of monthly migraine attacks	9.47
Primary outcome measure
Mean number of acute anti-migraine drugs avoided per month per subject (lower bound)
Total population (n = 413)	2.93
Attack users (n = 366)	3.31
Secondary outcome measures
Percentage of subjects using the device to treat attacks	88.6%
Percentage of attacks treated with the device	71.8%
Percentage of Cefaly®-treated attacks for which acute anti-migraine drug intake is reduced	42.6%
Other results
Proportion of drug classes with reduced intake
Triptans	54.9%
Analgesics/NSAIDs	64.9%
Others	10.7%
Percentage of subjects unable to reduce acute medication intake in any of their attacks	18.3%
Reasons for not using Cefaly® to treat migraine attacks
I cannot bear the feeling during an attack	14.9%
It does not provide sufficient relief	48.9%
I never tried	10.6%
I do not have the device with me during an attack	12.8%
Others	12.8%